Creative Diagnostics, a reagent supplier and developer focused on biologics quality control, has announced the launch of its new Viral Nucleic Acid Residue Assay Kits (qPCR) to ensure the purity and ...

PORTLAND, IA, UNITED STATES, January 9, 2025 /EINPresswire / -- The factors that are anticipated to impede the growth of the global nucleic acid therapeutics market during the forecast period include, ...

HOUSTON, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize ® liposomal delivery and antisense technology to develop ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Advancing Multiple Programs in Areas of Significant Unmet Medical Need Several Milestones Across Clinical Development Pipeline Expected in 2025 HOUSTON, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Bio-Path Hold ...

Professor Kevin J. Zwezdaryk and Chandler H. Monk discuss CRISPR and diagnostics, focusing on the development of a portable ...

NV ("etherna"), a technology platform leader pioneering mRNA and lipid-based nanoparticle (LNP) technologies, announces a ...

Protein barcoding has emerged as a powerful tool for multiplexed protein selection, analysis, and tracking, enabling advanced insights into proteomics research. Traditional detection methods, such as ...

Meiji Seika Pharma invests in MPM BioImpact's new technology and virology strategy to expand early-stage opportunities and ...

The UK Biobank project, announced today, aims to investigate how fluctuations in protein levels during mid- to late-life may influence <a target= ...

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo; President and Representative Director: Daikichiro Kobayashi, hereinafter "Meiji") announced that the company has concluded an investment agreement wi ...

Maravai LifeSciences Holdings said Wednesday it expects to report full-year revenue for 2024 near the midpoint of its most recent outlook. The San Diego company has guided for full-year revenue ...